Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging
Open Access
- 1 December 2013
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Nuclear Medicine Communications
- Vol. 34 (12), 1141-1149
- https://doi.org/10.1097/mnm.0000000000000008
Abstract
Dihydroxyphenylalanine (DOPA) is a neutral amino acid that resembles natural L-dopa (dopamine precursor). It enters the catecholamine metabolic pathway of endogenous L-DOPA in the brain and peripheral tissues. It is amenable to labeling with fluorine-18 (F) for PET imaging and was originally used in patients with Parkinson's disease to assess the integrity of the striatal dopaminergic system. The recent introduction and use of hybrid PET/CT scanners has contributed significantly to the management of a series of other pathologies including neuroendocrine tumors, brain tumors, and pancreatic cell hyperplasia. These pathologic entities present an increased activity of L-DOPA decarboxylase and therefore demonstrate high uptake of F-DOPA. Despite these potentially promising applications in several clinical fields, the role of F-DOPA has not been elucidated completely yet because of associated difficulties in synthesis and availability. Unfortunately, the available literature does not provide recommendations for procedures or administered activity, acquisition timing, and premedication with carbidopa. The aim of this paper is to outline the physiological biodistribution and normal variants, including possible pitfalls that may lead to misinterpretations of the scans in various clinical settingsKeywords
This publication has 35 references indexed in Scilit:
- GMP production of [18F]FDOPA and issues concerning its quality analyses as in USP “Fluorodopa F 18 Injection”Annals of Nuclear Medicine, 2011
- Non FDG PETClinical Radiology, 2010
- Non-FDG PET in the practice of oncologyIndian Journal of Cancer, 2010
- The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumorsEndocrine-Related Cancer, 2009
- [18F]-DOPA Positron Emission Tomography for Preoperative Localization in Congenital HyperinsulinismHormone Research in Paediatrics, 2008
- 6-l-18F-Fluorodihydroxyphenylalanine PET in Neuroendocrine Tumors: Basic Aspects and Emerging Clinical ApplicationsJournal of Nuclear Medicine, 2008
- Clinical Applications of PET in Brain TumorsJournal of Nuclear Medicine, 2007
- Fluorine-18-l-Dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography as a Tool to Localize an Insulinoma or β-Cell Hyperplasia in Adult PatientsJournal of Clinical Endocrinology & Metabolism, 2007
- Proposal for a Standardized Protocol for 18F-DOPA-PET (PET/CT) in Congenital HyperinsulinismHormone Research in Paediatrics, 2006
- Production of 6-[18F]fluoro-l-DOPA and its metabolism in vivo—a critical reviewInternational Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1992